(thirdQuint)Efficacy and Safety Study in Subjects With Asthma.

 The study will be a five-period cross-over study with each 7 day treatment period separated by a 7 day wash-out period.

 The study will enroll asthmatic subjects 18 years of age who are currently receiving inhaled corticosteroid treatment with an FEV1 of between 40-85% of predicted normal and with airway reversibility as demonstrated by an increase in FEV1 of 12% and 200ml .

 Efficacy assessments include 24-hour serial lung function testing.

 Safety assessments include incidence of adverse events and measurement of vital signs.

.

 Efficacy and Safety Study in Subjects With Asthma@highlight

The study is a multi-center, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of selected doses and dose intervals of the novel long acting beta agonist (LABA), GW642444 in asthmatic subjects 18 years of age who are currently receiving inhaled corticosteroid treatment.

